chinese pharmacopoeia
People's Republic of China (PRC) Pharmacopoeia was published by China Medical Science and Technology Press on June 5, 20 15, and was created by the State Pharmacopoeia Committee. It is the legal basis for drug research, production, management, use and supervision. All national drug standards should meet the relevant requirements of China Pharmacopoeia and its appendices.
It is published in four parts: the first part includes medicinal materials and decoction pieces, vegetable oil and extracts, prescription preparations and single-flavor preparations; The second part includes chemicals, antibiotics, biochemical drugs and radioactive drugs; Three collections of biological products; Four general principles of collection and loading, including: general principles of preparations, inspection methods, guiding principles, general principles related to reference substances and test solutions, pharmaceutical excipients, etc.
On July 2, 2020, the State Administration of Pharmaceutical Products and the National Health and Wellness Commission issued an announcement, officially announcing the 2020 edition of People's Republic of China (PRC) Pharmacopoeia. The new edition of China Pharmacopoeia was officially implemented on February 30th, 2020. The new edition of China Pharmacopoeia added 3 19 species, revised 3 177 species, no longer included 10 species, and adjusted and merged 4 species to include 591/kloc-0 species.
The new edition of Pharmacopoeia has further expanded the scope of collection and revision of drug varieties, with a total of 5608 varieties collected. 2598 varieties were collected, including 440 new varieties. In the second part, 2603 varieties were collected, including 492 new varieties.